BrainStorm Cell Therapeutics Partners with Pluri for NurOwn® Trials
BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) has recently announced an exciting new collaboration with Pluri Inc. (NASDAQ: PLUR) to enhance the manufacturing capabilities of NurOwn®, a breakthrough therapy aimed at treating neurodegenerative diseases, specifically amyotrophic lateral sclerosis (ALS). This partnership marks a significant milestone as both companies move forward in developing effective solutions for ALS patients.
Memorandum of Understanding Signed
The collaboration was formalized through a Memorandum of Understanding (MOU), allowing BrainStorm to initiate the transfer of its proprietary manufacturing technology to Pluri. With this agreement, production of NurOwn® will commence at Pluri's state-of-the-art manufacturing facility, ensuring high standards of quality control necessary for clinical trials.
Manufacturing Process and Clinical Support
Under the terms of the MOU, Pluri will deliver GMP-compliant manufacturing, reinforcing the supply chain needed for the planned Phase 3b trial of NurOwn®. This cooperation is strategic, as both companies are aiming to scale production effectively and prepare for potential future commercial distribution, subject to regulatory approval.
Haro Hartounian, PhD, Chief Operating Officer at BrainStorm, expressed confidence in Pluri's manufacturing capabilities, stating, "Pluri is recognized for its high-quality standards and regulatory compliance, making them an ideal partner for our clinical trials." The proximity of Pluri’s facility to BrainStorm’s R&D teams in Israel is expected to enhance communication and collaboration between the two teams.
The Importance of the Phase 3b Clinical Trial
The upcoming Phase 3b clinical trial is crucial for BrainStorm as it seeks to evaluate the efficacy of NurOwn® in ALS patients. The trial will enroll approximately 200 participants and will be conducted in two parts. In Part A, participants will receive either NurOwn® or a placebo, followed by an open-label period in Part B, where all patients will receive NurOwn®.
Goals for Clinical Trial Outcomes
The primary efficacy endpoint focuses on comparing changes in the ALS Functional Rating Scale-Revised (ALSFRS-R) between the NurOwn® group and the placebo group after 24 weeks. Success in this trial could pave the way for BrainStorm to submit a Biologics License Application (BLA) to the appropriate regulatory bodies, significantly accelerating the availability of NurOwn® for ALS patients.
Commitment to ALS Treatment and Future Prospects
BrainStorm plans to keep stakeholders updated, with an investor conference call scheduled for later this quarter. This call will provide further insights into the progress of the NurOwn® Phase 3 clinical program and the next steps moving forward.
Yaky Yanay, CEO of Pluri, reiterated his support for BrainStorm’s mission, emphasizing their eagerness to apply their extensive manufacturing expertise to facilitate the development of a novel therapy for ALS.
Navigating Challenges in Neurodegenerative Treatments
Developing effective treatments for ALS presents numerous challenges, and BrainStorm's commitment to innovative research and development is evident from its previous clinical studies. The NurOwn® technology utilizes autologous MSC-NTF cells, a unique approach that relies on cells obtained from patients themselves. These cells are cultivated to secrete neurotrophic factors that can benefit neurodegenerative conditions.
BrainStorm’s ongoing research has provided valuable insights into ALS pathology and treatment responses, contributing to a deeper understanding of disease mechanisms and progression.
About BrainStorm Cell Therapeutics
BrainStorm Cell Therapeutics Inc. specializes in the development of advanced cell therapies for treating debilitating neurodegenerative diseases. Their NurOwn® platform, which has garnered Orphan Drug designation from regulatory agencies, represents a pioneering endeavor in the fight against ALS. The company's commitment to research has led to multiple clinical trials, fostering optimism for future treatment breakthroughs in ALS and possibly other neurodegenerative conditions.
Through collaborative efforts and strategic partnerships like the one with Pluri Inc., BrainStorm is positioning itself as a key player in advancing cell therapy options for patients in need. As the clinical trials progress, the hope remains strong for translating research efforts into real-world treatments that can enhance the quality of life for ALS patients.
Frequently Asked Questions
What is the purpose of the collaboration between BrainStorm and Pluri?
The collaboration aims to enhance the manufacturing of NurOwn® for BrainStorm's Phase 3b clinical trial targeting ALS.
What is NurOwn®?
NurOwn® is a cell therapy developed to treat neurodegenerative diseases like ALS by using autologous MSC-NTF cells sourced from patients.
What are the objectives of the Phase 3b clinical trial?
The trial aims to evaluate the efficacy of NurOwn® in improving the condition of ALS patients through a well-defined treatment protocol.
How many participants will be enrolled in the trial?
Approximately 200 participants are expected to enroll in the two-part Phase 3b trial of NurOwn®.
What could a successful trial outcome mean for Missm? I
Success in the trial could lead to BrainStorm submitting a Biologics License Application for NurOwn®, accelerating its market availability for ALS treatment.
